ADC development: setbacks and key developments

The development of an antibody drug conjugate (ADC) is more unpredictable than that of a small molecule new chemical entity (NCE). As a result, the industry needs to invest in more vital research before conducting expensive clinical programs.

The single biggest challenge for the successful development of an ADC is the extreme difficulty in translating preclinical findings into predictions of clinical behaviour.

While several ADCs have failed to demonstrate their efficacy and safety, their rapid progression has meant that they can address the needs of patients suffering from cancers and improve therapeutic outcomes – particularly in areas where there are limited treatment options. ADC development is therefore recognised for its ability to achieve results where other therapeutics have failed.

Gianluca Franguelli, vice president of drug substance development, at Recipharm explores the key challenges faced when developing and bringing ADCs to market. He also shares his future predictions on these therapeutics. 

Read the full article here: